Target intelligence / Profile preview

Streptococcus pneumoniae serotype 9V capsular polysaccharide antigen (No widely recognized abbreviation; sometimes referred to as S. pneumoniae 9V CPS or PPS 9V in scientific literature, but usage is variable and not standardized)

Target
No widely recognized abbreviation; sometimes referred to as S. pneumoniae 9V CPS or PPS 9V in scientific literature, but usage is variable and not standardized
Molecular classification
Polysaccharide antigen, Bacterial capsular polysaccharide, Vaccine antigen, Other (bacterial surface component)
01

Overview

The Streptococcus pneumoniae serotype 9V capsular polysaccharide antigen is a complex carbohydrate molecule located on the surface of S. pneumoniae bacteria, composed of repeating sugar units with distinct structure and modifications (notably 6-O-acetylation of βManNAc via the wcjE gene). This capsule component is a critical virulence factor, protecting the pathogen from host immune mechanisms such as opsonization and phagocytosis, and is the primary target for antibody-mediated immunity induced by several pneumococcal vaccines. The 9V polysaccharide is included as an antigen in both plain polysaccharide and conjugate vaccine formulations, boosting serotype-specific immune responses to prevent invasive pneumococcal diseases. Protection by this molecule is strictly serotype-specific, and changes in serotype prevalence in response to vaccine usage represent a significant therapeutic challenge. Capsule antigens like 9V are not conventional "receptors" or enzymes but serve as distinct therapeutic targets for vaccine-induced immunity, forming the basis for the prevention of S. pneumoniae infections.

Other names
Streptococcus pneumoniae serotype 9V capsular polysaccharidePneumococcal serotype 9V capsule antigenS. pneumoniae type 9V polysaccharide antigenPPS 9V (in vaccine literature)9V capsulePneumococcal polysaccharide type 9V
02

Mechanism of action

Induction of actively acquired immunity: Vaccines containing the 9V capsular polysaccharide induce the production of specific antibodies that opsonize and facilitate clearance of S. pneumoniae serotype 9V from the host. In conjugate vaccines: Conjugation of the polysaccharide to a carrier protein (e.g., CRM197, a non-toxic mutant of diphtheria toxin) converts the response from T cell–independent to T cell–dependent, inducing immunological memory and enhancing efficacy especially in children.

03

Biological functions

Major determinant of bacterial virulenceEvasion of host immune response (prevents opsonophagocytosis)Induces serotype-specific antibody responseTarget of protective immunity in pneumococcal infection and vaccines
04

Disease associations

Infection (pneumococcal pneumonia, bacteremia, meningitis, and other invasive pneumococcal diseases)Pathogen virulence factor
05

Safety considerations

Serotype replacement: Use of vaccines targeting specific serotypes can alter circulating epidemiology, causing non-vaccine serotypes to become more prevalent.Poor immunogenicity in young children and immunocompromised individuals when administered as unconjugated polysaccharide (overcome by conjugate vaccine formulations).Rare risk of allergic or hypersensitivity reactions to vaccine componentsVaccine efficacy can be reduced in population groups with certain immunodeficiencies.
06

Interacting drugs

Pneumococcal vaccines (e.g., Pneumovax 23, Prevnar 13, and other vaccines containing purified or conjugated 9V polysaccharide antigen)

1 more in the full profile.

07

Biomarkers

Anti-capsular antibody titers specific for serotype 9V (used to monitor vaccine efficacy and immune status post-vaccination)No established small-molecule biomarkers

Beyond the preview

Go deeper on Streptococcus pneumoniae serotype 9V capsular polysaccharide antigen (No widely recognized abbreviation; sometimes referred to as S. pneumoniae 9V CPS or PPS 9V in scientific literature, but usage is variable and not standardized).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus pneumoniae serotype 9V capsular polysaccharide antigen (No widely recognized abbreviation; sometimes referred to as S. pneumoniae 9V CPS or PPS 9V in scientific literature, but usage is variable and not standardized).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call